Avita Medical Inc. (NASDAQ:RCEL) Stock Rated “Moderate Buy” by Wall Street Analysts

Avita Medical Inc. (NASDAQ:RCEL) has been given an average rating of “Moderate Buy” by the seven ratings firms that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $13.40.

RCEL has been the topic of several recent research reports. Lake Street Capital upped their price target on shares of Avita Medical from $8.00 to $12.00 and gave the company a “buy” rating in a report on Friday, August 28th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Avita Medical in a report on Monday, September 21st. Wall Street Zen raised Avita Medical from a “sell” rating to a “hold” rating in a report on Sunday, August 2nd. TD Cowen reissued a “buy” rating on shares of Avita Medical in a report on Tuesday, November 3rd. Finally, BTIG Research boosted their price target on Avita Medical from $15.00 to $21.00 and gave the company a “buy” rating in a report on Friday.

Avita Medical Price Performance

Shares of NASDAQ RCEL opened at $16.59 on Monday. The business’s 50 day moving average price is $12.77 and its 200 day moving average price is $6.85. The firm has a market cap of $521.26 million, a P/E ratio of -14.06 and a beta of 2.03. Avita Medical has a 52 week low of $3.22 and a 52 week high of $18.07.

Avita Medical (NASDAQ:RCEL) last issued its quarterly earnings results on Thursday, November 5th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.04. The business had revenue of $26.11 million during the quarter, compared to analyst estimates of $22.35 million. As a group, research analysts expect that Avita Medical will post -0.98 earnings per share for the current year.

Hedge Funds Weigh In On Avita Medical

Several large investors have recently made changes to their positions in the company. Russell Investments Group Ltd. increased its holdings in Avita Medical by 47.7% in the third quarter. Russell Investments Group Ltd. now owns 41,449 shares of the company’s stock valued at $486,000 after buying an additional 13,395 shares in the last quarter. Jefferies Financial Group Inc. purchased a new stake in shares of Avita Medical during the 3rd quarter worth about $440,000. China Universal Asset Management Co. Ltd. boosted its stake in shares of Avita Medical by 28.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 16,000 shares of the company’s stock worth $191,000 after acquiring an additional 3,500 shares in the last quarter. Harpswell Capital Advisors LLC acquired a new stake in shares of Avita Medical during the 3rd quarter valued at about $150,000. Finally, NewEdge Advisors LLC grew its position in shares of Avita Medical by 71.4% during the 2nd quarter. NewEdge Advisors LLC now owns 148,931 shares of the company’s stock valued at $615,000 after acquiring an additional 62,046 shares during the period. 27.66% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Avita Medical

Here are the key news stories impacting Avita Medical this week:

• Positive Sentiment: Raised revenue outlook: Avita lifted its full-year 2026 revenue guidance, signaling improved expectations for growth. AVITA Medical Raises Revenue Guidance
• Positive Sentiment: Q3 beat estimates: The company reported revenue of $26.11 million, above the $22.35 million analyst consensus, and a loss of $0.20 per share, narrower than the expected $0.24 loss. Another report said revenue surged 53% year over year. AVITA Medical Reports Third Quarter Results Q3 Revenue Growth
• Positive Sentiment: Analyst price target increased: BTIG Research raised its target from $15 to $21 and maintained a Buy rating, reflecting greater potential upside in its assessment. BTIG Raises Price Target
• Positive Sentiment: Medicare billing changes: A national physician payment framework and simplified billing codes for RECELL procedures are scheduled for 2027. These changes could ease billing complexity and support broader procedure adoption. Medicare Payment Framework and Billing Codes

Avita Medical Company Profile

Avita Medical, Inc (NASDAQ: RCEL) is a regenerative medicine company focused on developing and commercializing therapies that use a patient’s own cells to help restore damaged skin and tissue. Its lead product is the RECELL System, an autologous cell-harvesting device designed to prepare a suspension of a patient’s skin cells at the point of care for application to wounds.

RECELL is used in the treatment of certain thermal burn wounds and other skin injuries. The system is intended to support wound healing and may reduce the amount of donor skin required for grafting by enabling clinicians to create a cell suspension from a small sample of the patient’s healthy skin.